Summary by Moomoo AI
Kangxinuo Biotech (06185.HK) announced that its new vaccine CS-2036 under development has completed the first batch of 17 million doses. CS-2036 is a vaccine based on Virus-Like Particle (VLP) technology, which can mimic the structure of the virus to stimulate immune responses. CEO Xuefeng YU of Kangxinuo Biotech stated that this is an important advancement in the company's vaccine field, and looks forward to CS-2036 providing more effective disease prevention solutions in the future. The production completion date of CS-2036 is October 9, 2024, marking a crucial step forward in the company's vaccine research. The research team of Kangxinuo Biotech, including CEO Xuefeng YU and Shou Bai CHAO, are satisfied with the progress of the CS-2036 vaccine development and remain optimistic about its commercial prospects.